PRMT5-mediated methylation of LKB1 controls PD-L1 expression in NSCLC

June 1, 2026Biomedical JournalOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research explores how PRMT5 affects PD-L1 expression through LKB1 in non-small cell lung cancer.
Analyzed PRMT family expression using Oncomine, TCGA, and CPTAC databases.
Utilized pharmacological inhibitors and shRNA knockdown to assess PRMT5 effects on PD-L1.
Conducted mechanistic studies with co-immunoprecipitation and cycloheximide chase assays.
Higher PRMT5 levels correlated with reduced CD4+/CD8+ T-cell infiltration and increased PD-L1 expression.
PRMT5 inhibition decreased PD-L1 in LKB1-deficient cells but increased it in LKB1-proficient cells.
Combination of PRMT5 inhibitor and anti-PD-L1 antibody significantly enhanced T-cell activation.

We only have this paper's title and publication details.

Identifies PRMT5 as a key regulator of PD-L1 in NSCLC, suggesting LKB1 status as a predictive biomarker.

No takes yet. Share an insight, caveat, or question.

Shen et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share